Your gut microbiome is an ecosystem that contains trillions of bacterial organisms. These live microorganisms, also known as beneficial bacteria, can play key roles in gut function and overall health.
Diet and exercise are important to keep blood glucose under control, but often they’re not enough. Why? As we age, we get exposed to different environments and different stresses, our bodies lose specific beneficial bacteria that allow it to process carbohydrates, sugars and fibers effectively. These beneficial bacteria live along the length of your digestive tract and metabolize the food you eat, extracting beneficial nutrients from your diet. Without these microbes, your body cannot capture these nutrients and enzymes. Over time, your body loses its ability to keep your blood glucose under control.
Pendulum Glucose Control capsules are specifically designed for people with type 2 diabetes. They contain targeted strains of probiotics and a prebiotic that help restore the body’s natural ability to metabolize fiber in order to maintain healthy A1C and blood glucose levels.
Pendulum Glucose Control is a medical probiotic that contains targeted strains of probiotics (beneficial bacteria) and a prebiotic (food to fuel bacteria). This combination nourishes your ecosystem, enabling your body to increase butyrate production which assists in maintaining glucose control.
Good Gut Bacteria: Contains a blend of probiotics and a prebiotic that helps produce a beneficial short-chain fatty acid called butyrate. Butyrate is a key molecule needed to maintain insulin and glucose balance.
Blood Sugar: Shown in a clinical trial to reduce post-meal glucose spikes and A1C levels.*
Fiber Metabolism: Helps break down fiber to aid the body’s production of the metabolite butyrate, shown to be deficient in type 2 diabetes patients.
Gut Lining: Helps protect the gut lining in the intestines by helping prevent harmful bacteria from causing inflammation in the gut.
People with type 2 diabetes have been shown to be deficient in the specific gut microbes that metabolize fibers into short-chain fatty acids, like butyrate. Butyrate is a key molecule needed to maintain insulin and glucose balance.
Our medical research team is led by Chief Medical Officer, Orville Kolterman, M.D., a well-respected diabetes experts in the field based on his contributions in drug development and to the Diabetes community. Dr. Kolterman was previously the Chief Medical Officer at Amylin Pharmaceuticals, where he brought four diabetes drugs from early stage development through trials and to market.
Dr. Kolterman served as the President of the California Affiliate of the American Diabetes Association and is an Adjunct Professor of Medicine at the University of California, San Diego. Dr. Kolterman received his MD from Stanford University School of Medicine, performed his residency in Internal Medicine at the University of Chicago and returned to Stanford for his Endocrinology training.
Together with Orville, we work with leading diabetes professionals to ensure that our products deliver exceptional results and meet the highest standards of efficacy and safety.
“Pendulum Glucose Control has shown to deliver significant results and meets our highest standards of safety and efficacy.” Dr. Orville Kolterman, M.D.
In a clinical trial, Pendulum Glucose Control was shown to lower A1C levels and reduce post-meal blood sugar spikes in people with type 2 diabetes.*
Read more about the study:
*A nutrition study demonstrated statistically and clinically significant reduction in A1C and blood sugar spikes in people with type 2 diabetes. It was randomized, double-blinded, placebo controlled, and across multiple sites in the U.S. https://clinicaltrials.gov/ct2/show/NCT03893422?term=Whole+Biome&cond=Type+2+diabetes&cntry=US&state=US%3ACA&age=12&rank=1
Pendulum Glucose Control contains a proprietary probiotic blend: Clostridium beijerinckii WB-STR-0005, Clostridium butyricum WB-STR-0006, Akkermansia muciniphila WB-STR-0001, Eubacterium hallii WB-STR-0008, Bifidobacterium infantis 100. This page is intended to serve as notice under 35 U.S.C. § 287(a). [Pendulum Glucose Control] is covered by U.S. Pat. Nos. 9,173,910; 9,486,487; 10,149,867; 10,149,870. Other patents are pending.